Universtiy of Colorado Denver
Welcome,         Profile    Billing    Logout  
 7 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Messersmith, Wells
NCT03781154: Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors

Completed
3
31
US
Group Exercise
University of Colorado, Denver, American Cancer Society, Inc., Colorado State University
Colorectal Cancer
06/23
06/23
AGICC, NCT02723331: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Active, not recruiting
2
48
US
Nab paclitaxel, Abraxane, Gemcitabine, Gemzar
Academic Thoracic Oncology Medical Investigators Consortium, Celgene Corporation, Criterium, Inc., University of Colorado, Denver
Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
12/22
05/25
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
NCT02521844: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Active, not recruiting
1
89
US, RoW
ETC-1922159, Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities, PPD DEVELOPMENT, LP
Solid Tumors
10/24
10/24
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/26
02/28
NCT02955446: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

No Longer Available
N/A
US
PF-03084014, Gamma Secretase Inhibitor
University of Colorado, Denver, SpringWorks Therapeutics, Inc.
Neoplasm, Desmoid Tumor
 
 
Pollyea, Daniel Aaron
NCT03573024: Venetoclax and Azacitidine for Non-Elderly Adult Patients with Acute Myeloid Leukemia

Active, not recruiting
2
36
US
Azacitidine, Venetoclax
University of Colorado, Denver, AbbVie
Acute Myeloid Leukemia
06/26
06/27
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting
2
120
Europe, Canada, US
Cusatuzumab, OV-1001, Venetoclax, Azacitidine
OncoVerity, Inc.
Leukemia, Myeloid, Acute
01/27
06/27
NCT03564873: Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active, not recruiting
1/2
28
US
Omacetaxine, Phase 1, Azacitidine, Phase 2
University of Colorado, Denver
High Grade Myelodysplastic Syndromes
08/24
06/27
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT06429449: Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Recruiting
1
30
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Onureg, Vidaza, Mitoxantrone, Novantrone
University of Colorado, Denver, The Leukemia and Lymphoma Society
Leukemia, Myeloid Leukemia, Monocytic Leukemia
12/26
11/27
NCT04914845: KPT-9274 in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Recruiting
1
40
US
KPT-9274
University of Colorado, Denver, Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
02/26
02/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
Dabdoub, Lauren
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Recruiting
1/2
40
US
Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex,
Criterium, Inc., Novartis, Seagen Inc.
HER2-positive Metastatic Breast Cancer
08/24
06/25
Berens, Emily
NCT03564873: Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active, not recruiting
1/2
28
US
Omacetaxine, Phase 1, Azacitidine, Phase 2
University of Colorado, Denver
High Grade Myelodysplastic Syndromes
08/24
06/27
Visser, Ashley
NCT06141031: Trial of Radiotherapy in Combination with TTI-101 in Patients with Borderline Resectable Pancreatic Cancer

Suspended
1/2
35
US
TTI-101
University of Colorado, Denver, Tvardi Therapeutics, Incorporated
Pancreatic Cancer
09/27
09/28
NCT03564873: Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active, not recruiting
1/2
28
US
Omacetaxine, Phase 1, Azacitidine, Phase 2
University of Colorado, Denver
High Grade Myelodysplastic Syndromes
08/24
06/27

Download Options